Horizon Discovery is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, and CRISPR) able to alter almost any gene sequence in human or mammalian cell lines. Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer.
Dharmacon, now a part of Horizon, and a leader in custom RNA synthesis, was an early player in the field of RNA interference, contributing several key scientific findings and some of the first commercially siRNA reagents. Today, their areas of research and research tools have expanded to support all aspects of RNAi interference; siRNA, lentiviral shRNA, tools for microRNA research and genome-scale libraries for RNAi functional screens of genes, microRNAs and long non-coding RNAs. For over-expression, Dharmacon has one of the largest collections of cDNAs and ORFs commercially available.
